Japan five-year plan
Japan's Council on Economic and Fiscal Policy, an advisory panel to Prime Minister Shinzo Abe (chaired by the Premier himself), has submitted a recommendation entitled, The Basic Policies for Economic and Fiscal Reform 2007. The Abe Cabinet will now tackle several issues based on these.
The recommendation contains the main points mentioned in The Five-year Strategic Plan for Creating Innovative Drugs and Medical Devices, which were compiled and announced by the Ministry of Health, Labor and Welfare in April (Marketletter May 7), in order to enhance innovation and to boost international competitiveness.
The five-year plan proposes, among other things: accelerating drug approval reviews and improving their quality; improving the infrastructure and conditions of clinical trials; promoting appropriate evaluation of innovative drugs and medical devices; promoting the use of generic drugs; and reforming the National Health Insurance drug pricing system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze